Key result
Higher adherence to a hypertension digital therapeutic is linked to a ~6 mmHg greater SBP reduction.
Why the study?
The relative contributions of objective program adherence and subjective patient motivation to the blood pressure-lowering effects of digital therapeutics for hypertension remain unclear.
Does program adherence or patient motivation improve systolic blood pressure reduction in patients using a digital therapeutic for hypertension?
Cohort (n=198)
Does program adherence or patient motivation improve systolic blood pressure reduction in patients using a digital therapeutic for hypertension?
Answers are grounded in this paper and cite their sources.
Objective program adherence to a digital therapeutic for hypertension is more strongly associated with systolic blood pressure reduction than subjective patient motivation.
BACKGROUND: Although digital therapeutics (DTx) have shown efficacy for reducing the blood pressure (BP) of individuals with hypertension, the relative contributions of program adherence (objective) and patient motivation (subjective) to the antihypertensive effects of DTx remain unclear. METHODS: We analyzed data from the B-INDEX (Behavioral Modification Index) study, evaluating the BP-lowering effects by DTx. Program adherence was quantified using app-based usage metrics. Questionnaires assessed the DTx users' motivation. Associations between these factors and systolic BP (SBP) reduction were examined. RESULTS: Among 198 patients with hypertension (mean age 54.9 ± 10.6 years, 57.1% male, mean body mass index 26.7 ± 5.3 kg/m2, 57.6% taking antihypertensives), higher program adherence was associated with greater reductions in SBP at Week 24 (-8.0 vs -2.5 mmHg, p < 0.001), whereas higher motivation scores showed no significant association with SBP reduction (-7.3 vs -5.6 mmHg, p = 0.257). In contrast, body weight reduction and improvements in salt-intake scores showed similar patterns across adherence- and motivation-based subgroup analyses. CONCLUSIONS: Motivation is important for lifestyle modification, but objective program adherence was more strongly associated with SBP reduction than subjective motivation. Objective behavioral indices may better reflect lifestyle changes relevant to the antihypertensive effects of DTx. CLINICAL TRIAL REGISTRATION: UMIN000050479 (https://www.umin.ac.jp/ctr/).
No takes yet. Share an insight, caveat, or question.
Tomitani et al. (2026) conducted a cohort in hypertension (n=198). Higher program adherence to a digital therapeutic vs. Lower program adherence was evaluated on reduction in systolic BP (SBP) at Week 24 (p=<0.001). Higher objective program adherence to a digital therapeutic for hypertension was associated with greater reductions in systolic blood pressure at 24 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: